The current explosion of new areas of controversy in the treatment of acute lymphocytic leukemia in adults and young adults makes this comprehensive book a much needed reference for hematologists and oncologists. This book assembles leading authorities from around the globe to cover the full spectrum of ALL subtypes and their treatments. Specific topics of discussion include indications for allogeneic bone marrow transplant in first complete remission, the role of minimal residual disease in making treatment decisions, the treatment of young adults, and the treatment of Philadelphia chromosome positive ALL with the advent of the tyrosine kinase inhibitors. This is the first book to focus exclusively on the adult ALL patient. It provides a complete overview of diagnosis, molecular pathogenesis, evaluation, and treatment for this important patient population.Based on these unifying pheno- and genotypic features, CD56* B-ALL should be considered as a distinct disease entity. ... in cell-cycle progression and differentiation, in B- or T-ALL , for which surrogate markers or marker profiles remain undefined. ... expression or epigenetic studies, the classification of the acute leukemias, including ALL, has become a moving target. References 10. 11. 12. 13. 14.
|Title||:||Adult Acute Lymphocytic Leukemia|
|Author||:||Anjali S. Advani, Hillard M. Lazarus|
|Publisher||:||Springer Science & Business Media - 2010-11-18|